Found 27 matching trials
Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer PHASE1 This phase I trial studies the side effects and the best dose of Hsp90 inhi...
Show More Location
Jonsson Comprehensive Cancer Center
Learn More & Join Trial
AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer PHASE1 The purpose of this study is to find out what effects, administering infusi...
Show More Location
Multiple Locations
Learn More & Join Trial
AUY922 for Advanced ALK-positive NSCLC PHASE2 This research study is a Phase II clinical trial, which tests the safety an...
Show More Location
Massachusetts General Hospital
Learn More & Join Trial
Imaging HSP90 Inhibitor AUY922 on VEGF-89ZR-bevacizumab Positron Emission Tomography (PET) N/A Inhibition of Heat Shock Protein (HSP)90 is a new, promising treatment moda...
Show More Location
University Medical Center Groningen
Learn More & Join Trial
A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients PHASE2 A Phase II Study of AUY922, Novel HSP Inhibitor, in Patients with Advanced ...
Show More Location
National Health Research of Institutes, Taiwan Cooperative Oncology Group
Learn More & Join Trial
AUY922 in Patient With Stage IV NSCLC PHASE2 This is an open-label, single-arm, multicenter phase II trial in patients w...
Show More Location
National Cheng Kung University Hospital
Learn More & Join Trial
Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients PHASE1 This is a phase I/II, open-label, multicenter study of AUY922 administered ...
Show More Location
UCLA/ University of California Los Angeles UCLA
Learn More & Join Trial
Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies PHASE1 This phase I trial studies the side effects and best dose of Hsp90 inhibito...
Show More Location
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Learn More & Join Trial
A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma. PHASE1 This is a Phase I-Ib/II, open-label, multicenter study of AUY922 administer...
Show More Location
Mayo Clinic - Arizona Cancer Clinical Research Unit
Learn More & Join Trial
Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer PHASE2 A clinical trial to determine the effectiveness and safety of AUY922 compar...
Show More Location
USC/Kenneth Norris Comprehensive Cancer Center USC/Norris
Learn More & Join Trial